Loading company…
Purespring Therapeutics develops gene therapies for kidney diseases.
Purespring develops gene therapies targeting podocytes, including candidates for IgA nephropathy and other glomerular diseases. Founded in 2020 and based in London, UK, it raised GBP 80 million in Series B funding in October 2024, led by Sofinnova Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in